Company Filing History:
Years Active: 2025
Title: Grigoriy Shekhtman: Innovator in RNAi Therapeutics
Introduction
Grigoriy Shekhtman is a prominent inventor based in Los Angeles, CA, known for his significant contributions to the field of RNA interference (RNAi) therapeutics. With a total of 3 patents, he has made strides in developing innovative solutions for various medical conditions.
Latest Patents
Shekhtman's latest patents include groundbreaking work on RNAi agents designed to inhibit the expression of activin receptor-like kinase 7 (ALK7). This patent describes RNAi agents, compositions that include these agents, and methods for inhibiting the ALK7 gene. The ALK7 RNAi agents and their conjugates are designed to inhibit ALK7 gene expression, providing potential therapeutic benefits for conditions such as obesity, diabetes, and insulin resistance. Another significant patent focuses on RNAi agents that inhibit complement factor B (CFB) gene expression. This patent outlines pharmaceutical compositions that include CFB RNAi agents, which can be conjugated to targeting ligands for effective delivery to hepatocyte cells. These agents have potential applications in treating various diseases, including IgA nephropathy, lupus nephritis, and age-related macular degeneration.
Career Highlights
Grigoriy Shekhtman is currently associated with Arrowhead Pharmaceuticals, Inc., where he continues to advance his research in RNAi technologies. His work has been instrumental in developing novel therapeutic approaches that leverage RNAi for the treatment of complex diseases.
Collaborations
Throughout his career, Shekhtman has collaborated with notable colleagues, including Tao Pei and Zhi-Ming Ding, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Grigoriy Shekhtman's contributions to RNAi therapeutics exemplify the impact of innovative research in addressing critical health challenges. His patents reflect a commitment to advancing medical science and improving patient outcomes.